VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Male or female patients 2 to 16 years of age       │ Male or female patients 2 to 16 years of age       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who require at least 80% of their caloric │ Patients who require at least 80% of their caloric │     100 │
│ intake as PN at study start, and in whom an        │ intake as PN at study start, and in whom an        │         │
│ indication for PN is expected for at least 5 days  │ indication for PN is expected for at least 5 days  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who require a central venous line to      │ Patients who require a central venous line to      │     100 │
│ receive PN or already have a central venous line   │ receive PN or already have a central venous line   │         │
│ in place for other reasons                         │ in place for other reasons                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent from legal                │ Written informed consent from legal                │     100 │
│ representative(s)                                  │ representative(s)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to egg, soybean proteins,   │ Known hypersensitivity to egg, soybean proteins,   │     100 │
│ peanut proteins, corn or corn products, or to any  │ peanut proteins, corn or corn products, or to any  │         │
│ of the active substances or excipients             │ of the active substances or excipients             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe hyperlipidemia or severe disorders of lipid │ Severe hyperlipidemia or severe disorders of lipid │     100 │
│ metabolism characterized by hypertriglyceridemia   │ metabolism characterized by hypertriglyceridemia   │         │
│ (serum triglyceride concentration \>1,000 g/dL)    │ (serum triglyceride concentration >1,000 g/dL)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inborn errors of amino acid metabolism             │ Inborn errors of amino acid metabolism             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cardiopulmonary instability (including pulmonary   │ Cardiopulmonary instability (including pulmonary   │     100 │
│ edema, cardiac insufficiency, myocardial           │ edema, cardiac insufficiency, myocardial           │         │
│ infarction, acidosis and hemodynamic instability   │ infarction, acidosis and hemodynamic instability   │         │
│ requiring significant vasopressor support)         │ requiring significant vasopressor support)         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemophagocytic syndrome                            │ Hemophagocytic syndrome                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ PN in the last 7 days prior to study enrollment    │ PN in the last 7 days prior to study enrollment    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Need for chronic PN before study start             │ Need for chronic PN before study start             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver enzymes (either AST, ALT, GGPT), or direct   │ Liver enzymes (either AST, ALT, GGPT), or direct   │     100 │
│ bilirubin exceeding 2 x upper limit of normal      │ bilirubin exceeding 2 x upper limit of normal      │         │
│ range                                              │ range                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pathologically altered level of any serum          │ Pathologically altered level of any serum          │     100 │
│ electrolyte (sodium, potassium, magnesium,         │ electrolyte (sodium, potassium, magnesium,         │         │
│ calcium, chloride, phosphate) unless corrected     │ calcium, chloride, phosphate) unless corrected     │         │
│ prior to the start of study treatment              │ prior to the start of study treatment              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pathologically altered blood pH, or oxygen         │ Pathologically altered blood pH, or oxygen         │     100 │
│ saturation, or carbon dioxide unless corrected     │ saturation, or carbon dioxide unless corrected     │         │
│ prior to the start of study treatment              │ prior to the start of study treatment              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or lactation                             │ Pregnancy or lactation                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another clinical study            │ Participation in another clinical study            │     100 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 2 Years  │ Male or female patients 2 to 16 years of age │      42 │
├───────────────────────────────────┼──────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 16 Years │ Male or female patients 2 to 16 years of age │      49 │
╘═══════════════════════════════════╧══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 93.94444444444444
OverAll Ratio: 95.97222222222223
